Literature DB >> 9075813

Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene.

P Denny1, C J Lord, N J Hill, J V Goy, E R Levy, P L Podolin, L B Peterson, L S Wicker, J A Todd, P A Lyons.   

Abstract

Currently, 16 loci that contribute to the development of IDDM in the NOD mouse have been mapped by linkage analysis. To fine map these loci, we used congenic mapping. Using this approach, we localized the Idd3 locus to a 0.35-cM interval on chromosome 3 containing the Il2 gene. Segregation analysis of the known variations within this interval indicated that only one variant, a serine-to-proline substitution at position 6 of the mature interleukin-2 (IL-2) protein, consistently segregates with IDDM in crosses between NOD and a series of nondiabetic mouse strains. These data, taken together with the immunomodulatory role of IL-2, provide circumstantial evidence in support of the hypothesis that Idd3 is an allelic variation of the Il2 gene, or a variant in strong linkage disequilibrium.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9075813     DOI: 10.2337/diab.46.4.695

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  26 in total

1.  Chromosome substitution strains: some quantitative considerations for genome scans and fine mapping.

Authors:  John K Belknap
Journal:  Mamm Genome       Date:  2003-11       Impact factor: 2.957

Review 2.  From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era.

Authors:  Alan G Baxter; Margaret A Jordan
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Immunology of IDDM.

Authors:  H Noorchashm; W Kwok; A Rabinovitch; L C Harrison
Journal:  Diabetologia       Date:  1997-10       Impact factor: 10.122

4.  Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping.

Authors:  P A Lyons; N Armitage; F Argentina; P Denny; N J Hill; C J Lord; M B Wilusz; L B Peterson; L S Wicker; J A Todd
Journal:  Genome Res       Date:  2000-04       Impact factor: 9.043

Review 5.  The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy.

Authors:  Chris Fraker; Allison L Bayer
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

6.  Genetic interactions among Idd3, Idd5.1, Idd5.2, and Idd5.3 protective loci in the nonobese diabetic mouse model of type 1 diabetes.

Authors:  Xiaotian Lin; Emma E Hamilton-Williams; Daniel B Rainbow; Kara M Hunter; Yang D Dai; Jocelyn Cheung; Laurence B Peterson; Linda S Wicker; Linda A Sherman
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

7.  Identification of a novel type 1 diabetes susceptibility gene, T-bet.

Authors:  Yuka Sasaki; Kenji Ihara; Nobuo Matsuura; Hitoshi Kohno; Seiho Nagafuchi; Ryuichi Kuromaru; Koichi Kusuhara; Ryu Takeya; Timothy Hoey; Hideki Sumimoto; Toshiro Hara
Journal:  Hum Genet       Date:  2004-07-06       Impact factor: 4.132

8.  Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease.

Authors:  L Geng; M Solimena; R A Flavell; R S Sherwin; A C Hayday
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

9.  IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease.

Authors:  Eva d'Hennezel; Mara Kornete; Ciriaco A Piccirillo
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

10.  Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus.

Authors:  Helen M McGuire; Alexis Vogelzang; Natasha Hill; Malin Flodström-Tullberg; Jonathan Sprent; Cecile King
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.